Pathology Unit, Department of Molecular and Translational Medicine-DMMT, University of Brescia, Brescia, Italy.
Pathology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Virchows Arch. 2024 Jul;485(1):43-51. doi: 10.1007/s00428-023-03682-8. Epub 2023 Oct 26.
Evaluation of B-cell clonality can be challenging in the interpretation of lymphoid infiltrates on tissue sections. Clonality testing based on IG gene rearrangements analysis by PCR (IG-PCR) is the gold standard. Alternatively, B-cell clonality can be assessed by the recognition of immunoglobulin light chain (IgLC) restriction, by immunohistochemistry (IHC), chromogenic in situ hybridization (ISH) or flow cytometry (FC). IG-PCR requires molecular facilities, and FC requires cell suspensions, both not widely available in routine pathology units. This study evaluates the performance of B-cell clonality detection by IgLC-RNAscope® (RNAsc) in a group of 216 formalin-fixed, paraffin-embedded samples including 185 non-Hodgkin B-cell lymphomas, 11 Hodgkin lymphomas (HL) and 20 reactive samples. IgLC-RNAsc, performed in parallel with FC in 53 cases, demonstrated better performances (93% vs 83%), particularly in diffuse large B-cell lymphoma (98% vs 71%) and follicular lymphoma (93% vs 83%) diagnosis. IgLC-RNAsc was also superior to IHC and ISH especially in samples with limited tumor cell content, where IG-PCR was not informative. Performed for the first time on mediastinal lymphomas, IgLC-RNAsc identified monotypic IgLC transcripts in 69% of primary mediastinal large B-cell lymphoma (PMBCL) and 67% of mediastinal gray zone lymphomas (MGZL). IGK/L double-negative cells were detected in 1 PMBCL, 2 MGZL, and all classical HL, while monotypic IgLC expression appeared to be a hallmark in nodular lymphocyte-predominant HL. IgLC-RNAsc demonstrates to be a powerful tool in B-cell lymphoma diagnosis, above all in challenging cases with limited tumor cell content, ensuring in situ investigations on mechanisms of Ig regulation across lymphoma entities.
B 细胞克隆性的评估在组织切片中对淋巴细胞浸润的解读具有挑战性。基于聚合酶链反应 (PCR) 的 IG 基因重排分析的克隆性检测是金标准。或者,可以通过免疫组化 (IHC)、显色原位杂交 (ISH) 或流式细胞术 (FC) 识别免疫球蛋白轻链 (IgLC) 限制来评估 B 细胞克隆性。PCR 需要分子设施,FC 需要细胞悬浮液,这两者在常规病理单位都不广泛可用。本研究评估了 IgLC-RNAscope®(RNAsc)在包括 185 例非霍奇金 B 细胞淋巴瘤、11 例霍奇金淋巴瘤 (HL) 和 20 例反应性样本的 216 例福尔马林固定、石蜡包埋样本中的 B 细胞克隆性检测性能。在 53 例病例中与 FC 平行进行的 IgLC-RNAsc 显示出更好的性能 (93%对 83%),特别是在弥漫性大 B 细胞淋巴瘤 (98%对 71%)和滤泡性淋巴瘤 (93%对 83%)诊断中。与 IHC 和 ISH 相比,IgLC-RNAsc 也具有优势,尤其是在肿瘤细胞含量有限的样本中,IG-PCR 没有信息。首次在纵隔淋巴瘤中进行的 IgLC-RNAsc 在 69%的原发性纵隔大 B 细胞淋巴瘤 (PMBCL)和 67%的纵隔灰色区淋巴瘤 (MGZL)中鉴定出单型 IgLC 转录本。在 1 例 PMBCL、2 例 MGZL 和所有经典 HL 中检测到 IGK/L 双阴性细胞,而单型 IgLC 表达似乎是结节性淋巴细胞为主型 HL 的一个标志。IgLC-RNAsc 证明是 B 细胞淋巴瘤诊断的有力工具,尤其是在肿瘤细胞含量有限的具有挑战性的病例中,确保对淋巴瘤实体中 Ig 调节机制进行原位研究。